Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aurinia Pharmaceuticals

Division of Aurinia Pharmaceuticals Inc.

Latest From Meiji Seika Pharma Co. Ltd.

Pipeline Watch: Phase III Starts With Fitusiran In Hemophilia, Zoliflodacin In Gonorrhea, Opdivo Combo In RCC

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Deals Shaping The Medical Industry, May 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Deal-making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in April 2017.

Deals BioPharmaceutical

Japan Delays Keytruda Pricing Amid PD-1 Cost Concerns

Regulatory authorities in Japan have put back the granting of a reimbursement price to Keytruda under the national health insurance system amid rising worries over the cost of new cancer immunotherapies, delaying the launch of the product for now.

Japan Reimbursement

Deal Watch: Novartis, Cerulean Team To Develop Nanoparticle-Drug Conjugates

Leveraging the brain power behind the first approved IPF drug, Esbriet, small companies Antegrin and Cascadia merge to form the fibrosis-centered Indalo Therapeutics. Gedeon Richter in-licenses a biosimilar of Roche’s Herceptin.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Renal System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Aurinia Pharmaceuticals Inc.
  • Senior Management
  • Stephen W Zaruby, Pres. & CEO
    Dennis Bourgeault, CFO
    Neil Solomons, CMO
  • Contact Info
  • Aurinia Pharmaceuticals
    Phone: (250) 744-2488
    4464 Markham St.
    Ste. 1203
    Victoria, V8Z748
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register